Gene Therapy: Indefinite Delivery/Indefinite Quantity (IDIQ) Analytic and Operational Support for the Engagement of the Public and Patients (AOSEPP)
Given the recent approvals of gene-therapy-based interventions, including gene-editing-based therapies (Luxturna) and chimeric antigen receptor T cell (CAR-T) therapies (Yescarta, Kymriah), there is growing interest in better understanding the evidence supporting these therapies, the evidence gaps around these interventions, and future gene therapies that may currently be in development.
The Patient-Centered Outcomes Research Institute (PCORI) sought further information on recent advances in gene therapies for the treatment of human disease that can be summarized in a report for public distribution. Find out more under the "Scope" section in the RFP.
Successful Offeror: RAND Corporation
Award Amount: $99,944
Posted: May 29, 2018
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
